US biotech PureTech is to develop its most advanced pipeline drug LYT-100 as a potential treatment for inflammation and lung scarring in patients who have serious cases of COVID-19 or who have ...

LYT-100 is wholly owned by PureTech, which is already being developed for conditions involving inflammation and fibrosis and disorders of lymphatic flow. The rationale for treating inflammation ...

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 ...

Analysts view LYT-100 as the most promising program within PureTech's portfolio, with recent data supporting the drug's potential in addressing the substantial unmet medical need within the IPF ...

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 ...

PureTech previously announced that it intends to advance LYT-200 via its Founded Entity, Gallop Oncology. LYT-200 is a fully human IgG4 monoclonal antibody targeting a foundational oncogenic and ...

1 Day LYT 89.41% DJIA -0.37% Russell 2K -0.39% Media/Entertainment -3.97% ...

The FDA has also granted orphan drug designation to LYT-200 for the treatment of AML a BOSTON, January 08, 2025--PureTech to present at 43rd annual J.P. Morgan Healthcare Conference. BOSTON ...